Evidence map›Paper›PMID 25246489›Full record

Trial reportAlcohol and alcoholism (Oxford, Oxfordshire)2014

Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.

K C Morley, A Baillie, S Leung, G Addolorato, L Leggio, P S Haber

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alcohol and alcoholism (Oxford, Oxfordshire), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Baclofen in the treatment of alcohol use disorder: tailored doses matter.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. GABACurrent topics in behavioral neurosciences · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

K C MorleyNHMRC Centre of Research Excellence in Mental Health and Substance Use, Discipline of Addiction Medicine, University of Sydney, Sydney, NSW, Australia kirsten.morley@sydney.edu.au.
A BaillieNHMRC Centre of Research Excellence in Mental Health and Substance Use, Department of Psychology, Macquarie University, Sydney, NSW, Australia.
S LeungCentral Clinical School, University of Sydney, Sydney, NSW, Australia.
G AddoloratoInstitute of Internal Medicine, Catholic University of Rome, Rome, Italy.
L LeggioSection on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.
P S HaberNHMRC Centre of Research Excellence in Mental Health and Substance Use, Discipline of Addiction Medicine, University of Sydney, Sydney, NSW, Australia Drug Health Services, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
University of Sydney · AUNational Health and Medical Research Council · AUNational Institutes of Health · USRoyal Prince Alfred Hospital · AUUniversità Cattolica del Sacro Cuore · IT

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIAAA000218 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LEGGIO, LORENZO · 2013 to 2020
$22.8M
6 · The paper itself

Abstract

aimTo conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence.

methodsOut of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment.

resultsIntention-to-treat analyses revealed that alcohol consumption (heavy drinking days, drinks per drinking day) significantly reduced across all three groups during the treatment period. There were no statistically significant advantages to treatment on time to first heavy drinking day (relapse) (P = 0.08), nor time to first drink (lapse) (P = 0.18). A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0.05). There was also a beneficial effect for baclofen 60 mg/day relative to placebo on time to relapse in this comorbid group (P < 0.05). Both doses of baclofen were well tolerated. There were no serious adverse events.

conclusionsIn spite of the small sample for a 3-arm clinical trial, this study suggests a specific role of baclofen in alcohol-dependent individuals with comorbid anxiety. Replication in larger, fully-powered studies is required.

Indexed as

AdultAlcohol AbstinenceAlcoholismAnxietyBaclofenDouble-Blind MethodFemaleGABA-B Receptor AgonistsHumansMaleMiddle AgedRecurrenceTreatment OutcomeBaclofenGABA-B Receptor Agonists

Identifiers

PMID25246489
PMCPMC4804107
OpenAlexW2136475835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.